Prostate Cancer Patients Can Benefit from 5-alpha-reductase Inhibitor Treatment: a Meta-analysis

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2020 Jun 18

PMID 32547884

Citations 4

Authors

Tuo Deng

Xueming Lin

Xiaolu Duan

Zihao He

Zhijian Zhao

Guohua Zeng

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy and safety of 5α-reductase inhibitors (5ARIs) in treating prostate cancer (PCa) have not been fully determined. We performed a meta-analysis to evaluate the effectiveness and safety of 5ARIs for PCa patients.

Methods: A comprehensive literature search of online databases was conducted to obtain comparative studies exploring the effectiveness and safety of 5ARIs in treating PCa up to October 2019. Summarized odds ratio s (OR s) or hazard ratio s (HR s) were calculated to compare the outcomes between 5ARI and control groups. Our meta-analysis was registered in PROSPERO under number CRD42018109809.

Results: A total of 2,277 patients from 10 studies were included. No significant difference was found in prostate-specific antigen progression between two groups (OR = 0.82, 95% CI [0.52-1.29], = 0.40). However, 5ARI treatment significantly reduced the total progression of PCa (OR = 0.61, 95% CI [0.48-0.77], < 0.0001), especially for patients with local (OR = 0.56, 95% CI [0.44-0.73], < 0.00001) and low-Gleason score (≤7) PCa (OR = 0.63, 95% CI [0.48-0.84], = 0.002). Additionally, 5ARIs also significantly prolonged the progression-free survival time (HR = 0.57, 95% CI [0.34-0.96], = 0.04) for PCa patients. No significant difference was found in the occurrence of PCa recurrence, metastasis, biopsy reclassification, and side-effects between two groups.

Conclusions: Our study suggests that 5ARI treatment can benefit patients with local and low Gleason score (≤7) PCa, especially in delaying the disease progression. More studies with larger sample size and comprehensive study design are still needed to verify our outcomes.

Citing Articles

5-alpha reductase inhibitors use in prostatic disease and beyond.

Chislett B, Chen D, Perera M, Chung E, Bolton D, Qu L Transl Androl Urol. 2023; 12(3):487-496.

PMID: 37032761 PMC: 10080355. DOI: 10.21037/tau-22-690.

and Mixture Improves Benign Prostatic Hyperplasia in Rats by Regulating Androgen Receptor Signaling and Apoptosis.

Kim M, Tran P, Yin J, Song J, Kim H Nutrients. 2023; 15(4).

PMID: 36839177 PMC: 9959710. DOI: 10.3390/nu15040818.

Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.

Nair-Shalliker V, Bang A, Egger S, Yu X, Chiam K, Steinberg J Br J Cancer. 2022; 127(4):735-746.

PMID: 35610365 PMC: 9381576. DOI: 10.1038/s41416-022-01827-1.

A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study.

Barrett T, Pacey S, Leonard K, Wulff J, Funingana I, Gnanapragasam V Eur Urol Open Sci. 2022; 38:17-24.

PMID: 35495285 PMC: 9051967. DOI: 10.1016/j.euros.2022.01.007.

References

Andriole G, Roehrborn C, Schulman C, Slawin K, Somerville M, Rittmaster R . Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004; 64(3):537-41. DOI: 10.1016/j.urology.2004.04.084. View

Dutkiewicz S . Comparison of maximal and more maximal intermittent androgen blockade during 5-year treatment of advanced prostate cancer T3NxMx-1. Int Urol Nephrol. 2011; 44(2):487-92. DOI: 10.1007/s11255-011-0051-6. View

Maria McCrohan A, Morrissey C, OKeane C, Mulligan N, Watson C, Smith J . Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer. 2006; 106(12):2743-52. DOI: 10.1002/cncr.21938. View

McConnell J, Wilson J, George F, Geller J, Pappas F, Stoner E . Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992; 74(3):505-8. DOI: 10.1210/jcem.74.3.1371291. View

Masoodi K, Garcia R, Pascal L, Wang Y, Ma H, OMalley K . 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013; 154(7):2296-307. PMC: 3689274. DOI: 10.1210/en.2012-2077. View

Ross A, Feng Z, Pierorazio P, Landis P, Walsh P, Carter H . Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int. 2012; 110(5):651-7. PMC: 6489446. DOI: 10.1111/j.1464-410X.2011.10875.x. View

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F . Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362(13):1192-202. DOI: 10.1056/NEJMoa0908127. View

Litwin M, Tan H . The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017; 317(24):2532-2542. DOI: 10.1001/jama.2017.7248. View

Fleshner N, Lucia M, Egerdie B, Aaron L, Eure G, Nandy I . Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379(9821):1103-11. DOI: 10.1016/S0140-6736(11)61619-X. View

10.

Preston M, Wilson K, Markt S, Ge R, Morash C, Stampfer M . 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014; 174(8):1301-7. PMC: 4122627. DOI: 10.1001/jamainternmed.2014.1600. View

11.

Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L . The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349(3):215-24. DOI: 10.1056/NEJMoa030660. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Schmidt L, Regan K, Anderson S, Sun Z, Ballman K, Tindall D . Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate. 2009; 69(16):1730-43. PMC: 2783419. DOI: 10.1002/pros.21022. View

14.

Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D . Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995; 45(3):491-7. DOI: 10.1016/s0090-4295(99)80021-1. View

15.

Dai C, Ganesan V, Zabell J, Nyame Y, Almassi N, Greene D . Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. J Urol. 2017; 199(2):445-452. DOI: 10.1016/j.juro.2017.08.006. View

16.

Cooperberg M, Lubeck D, Meng M, Mehta S, Carroll P . The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22(11):2141-9. PMC: 2997214. DOI: 10.1200/JCO.2004.10.062. View

17.

Luo L, Yang R, Wang J, Zhao S, Liu Y, Zhu Z . Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis. Asian J Androl. 2019; 22(5):532-538. PMC: 7523616. DOI: 10.4103/aja.aja_112_19. View

18.

Thomas L, Douglas R, Lazier C, Too C, Rittmaster R, Tindall D . Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2007; 53(2):244-52. DOI: 10.1016/j.eururo.2007.10.052. View

19.

Chu F, Sartor O, Gomella L, Rudo T, Somerville M, Hereghty B . A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. Eur J Cancer. 2015; 51(12):1555-69. DOI: 10.1016/j.ejca.2015.04.028. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View